New drug combo shows promise for tough liver cancers
NCT ID NCT05644379
First seen Feb 11, 2026 · Last updated Apr 30, 2026 · Updated 12 times
Summary
This study tests a combination of two drugs, cadonilimab and regorafenib, in 30 adults with advanced liver cancer that has not responded to at least one prior therapy. The goal is to see if the combination can shrink tumors or slow disease progression, while monitoring side effects. Participants must have a specific level of liver function and measurable tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA THAT HAS FAILED AT LEAST ONE PRIOR SYSTEMIC THERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, 300308, China
Conditions
Explore the condition pages connected to this study.